BASILEA N | 38,550 / -0,90% |
Data / Laikas | 04.07. / 17:30 |
Pok. / Pok.(%) | -0,350 / -0,90% |
Bid | 38,200 / 394 |
Ask | 39,500 / 300 |
Atidaryti | 39,200 |
Ankstesnį uždaryti | 38,900 |
Aukšč. | 39,600 |
Žem. | 38,200 |
APYVARTA [CHF] | 891.635,400 |
APYVARTA [Units] | 23.033 |
Price fixings | 257 |
ISIN | CH0011432447 |
Simbolis | BSLN |
Birža | SIX Swiss Exchange |
Rūšis | Stock |
Birža | Paskutinis | APYVARTA | |
---|---|---|---|
SIX Swiss Ex.. | 38,550 | ![]() |
23.033 |
London Domes.. | 38,55 | ![]() |
2.752 |
Cboe Europe .. | 38,25 | ![]() |
644 |
Cboe Europe .. | 38,25 | ![]() |
230 |
Turquoise | 38,50 | ![]() |
129 |
Lang & Schwa.. | 38,15 | ![]() |
|
Nasdaq Other.. | 41,0000 | 40 | |
München | 32,300 | 0 | |
Berlin | 32,100 | 0 | |
Frankfurt | 32,2800 | 0 | |
gettex | 32,340 | ||
TradeGate | 30,300 | 33 | |
EUREX | Options |
Naujienos
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire